Fig 2: Investigating the clinical predictive value of CD8A in prognosis and immunotherapeutic response. (A–E) Kaplan–Meier plots of CD8A in five datasets, including TCGA (A), GSE48277 (B), GSE48075 (C), GSE93157 (D) and IMvigor210 (E). (F) Percentages of the different PD-L1 inhibitor responses between high or low CD8A expression groups in IMvigor210. (G) Forest plot of the HRs for patients with high CD8A expression compared to patients with low CD8A expression in seven BCa datasets. (H) Univariate and multivariate Cox analyses in TCGA-BCa. OS, overall survival; PFS, progression-free survival; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR: hazard ratio; TCGA: The Cancer Genome Atlas; BCa, bladder cancer.

Fig 3: Biological analysis of CD8A. (A) Gene set enrichment analysis for comparing biological pathways between high and low CD8A expression groups. (B) Gene set variation analysis analyzed the different biological pathways between high and low CD8A expression groups. (C) The different levels of TME scores between low and high CD8A expression groups. (D) The association of CD8A with TIICs and critical immune checkpoint genes. (E) Patient 1: an 88-year-old man with MIBC and IHC-based CD8A high expression. (F) Patient 2: a 65-year-old man with MIBC and IHC-based CD8A low expression. TME, tumor microenvironment; TIICs, tumor-infiltrating immune cells; IHC, immunohistochemistry; MIBC, muscle-invasive bladder carcinoma. *: p < 0.05, ***: p < 0.001.

Fig 4: Combination of SOX and anti-TIGIT is beneficial to CD8+ T cells proliferation and IFN-γ release. (a, b) CD8+ TIL cells were treated with SOX, Anti-TIGIT, or SOX +Anti-TIGIT. Immunofluorescence was used to detect expression levels of KI-67. (c, d) CD8+ TIL cells were treated with SOX, Anti-TIGIT, or SOX +Anti-TIGIT, and stimulated with PMA for 5 h. Frequency and number of IFN-γ of CD8+ cells were quantified. *P < 0.05, **P < 0.01.

Fig 5: The expression of c-Myc is negatively correlated with T-cell infiltration in many solid tumors.A Analysis of the correlation between c-Myc expression and CD45, CD4, CD8 expression in LUSC, SKCM, HNSC, UVM, AML, and LGG (TCGA dataset). B Correlation between c-Myc expression and immune cell marker expression in osteosarcoma (GEO dataset, GSE33382). C The relationship between the expression of c-Myc, CD4, CD8, CD19, CD80, F4/80, and the prognosis of osteosarcoma (TARGET database). D Representative pictures of immunohistochemical staining of c-Myc, CD4, and CD8 in 80 human osteosarcoma samples. scale bar: 100 μm. Statistical comparisons were performed using Fisher’s exact test (E).